lundi 28 septembre 2015

Onco Actu du 28 septembre 2015 - Spécial ECC 2015

5.6 ESMO

Call to improve radiotherapy access around world [BBC News]

Six New Countries Join the List of ESMO Designated Centres of Integrated Oncology and Palliative Care [ESMO]

The Lancet Oncology Press Release: Tackling the Global Shortfall in Radiotherapy Could Save Millions of Lives and Boost the Economy of Poorer Countries [ESMO]

ESMO Commentary: Migrants, Refugees and Neglected Patient Populations: nationality and social status still affect cancer care quality [ESMO]

5.6.1 ESMO - Essais

Novartis drug Afinitor® significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NET [Novartis]

New Data from KEYNOTE-028, Merck’s Trial Evaluating KEYTRUDA® (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress [Merck]

Regional Hyperthermia Added to Neoadjuvant Chemotherapy Doubles Length of Overall Survival in Patients With Localised High-Risk Soft Tissue Sarcoma [ESMO]

Rare cancer responds unusually well to new treatment: results from the NETTER-1 trial [ESMO]

Results of International Trial Show Promise in Rare, Difficult to Treat Cancer: results from the RADIANT-4 trial [ESMO]

Progression-Free Survival Prolonged with Everolimus in Patients with Advanced Lung/Gastrointestinal Neuroendocrine Tumours [ESMO]

5.6.10 ESMO - Vessie

Roche says new drug shows benefits in lung, bladder cancer tests [Reuters]

Roche presents positive results from pivotal study of investigational immunotherapy atezolizumab in specific type of advanced bladder cancer at 2015 European Cancer Congress [Roche]

Novel Atezolizumab Shows Promise in Metastatic Urothelial Carcinoma [ESMO]

5.6.11 ESMO- Rein

Bristol, Exelixis Drugs Demonstrate Treatment Benefit in Kidney Cancer [TheStreet]

Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated Advanced Renal Cell Carcinoma [BMS]

Two Kidney Cancer Drugs Show Promise in Separate Studies [Wall Street Journal]

Two new kidney cancer drugs 'work' [BBC News]

Bristol's Opdivo boosts kidney cancer survival beyond two years [Reuters]

Cabozantinib Out-Performs Everolimus in Advanced Renal Cell Carcinoma [ESMO]

Nivolumab Improves Overall Survival in Patients with Advanced Kidney Cancer: results from the CheckMate 025 trial [ESMO]

Cabozantinib Improves Survival in Patients with Advanced Kidney Cancer: results from the METEOR trial [ESMO]

2 New Drugs Prove More Effective Against Kidney Cancer, Studies Find [NY Times]

5.6.12 ESMO - Observation

Primary Surgery is Associated with Survival Benefit in Patients with Advanced Cancers of the Throat [ESMO]

EUROCARE Results Show Large Variations in Survival from Blood Cancers Between European Countries [ESMO]

Childhood Cancers in Europe: progress has been made, but much remains to be done, says major report [ESMO]

Treatment of elderly patients with breast cancer varies between different countries throughout Europe [ESMO]

ESMO Commentary: The variable access to best cancer care in Europe may affect clinical outcomes and survival in older patients [ESMO]

5.6.13 ESMO - Prostate

Anti-tumour Activity Demonstrated with Orteronel in Metastatic Castration Resistant Prostate Cancer [ESMO]

5.6.2 ESMO - Divers

Aspirin can double life expectancy of those with common cancers [The Telegraph]

Genetic Screening of Brain Metastases Could Reveal New Targets for Treatment [ESMO]

Post Diagnosis Aspirin Improves Survival in all Gastrointestinal Cancers [ESMO]

5.6.4 ESMO - Poumon

VARGATEF® plus docetaxel significantly reduced tumour burden in lung cancer patients with advanced adenocarcinoma compared to docetaxel alone [Boehringer Ingelheim]

GIOTRIF® (afatinib) demonstrates superior survival compared to Tarceva® (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status [Boehringer Ingelheim]

Two positive studies of Roche’s investigational cancer immunotherapy atezolizumab in specific type of lung cancer presented at 2015 European Cancer Congress [Roche]

ESMO Commentary: Atezolizumab Set to Change Refractory Lung Cancer Treatment [ESMO]

Nivolumab Improves the Proportion of Lung Cancer Patients Alive After More Than a Year [ESMO]

5.6.5 ESMO - Mélanome & Peau

Induction with Nivolumab Followed by Ipilimumab Most Effective Temporal Approach in Non-Resectable Melanoma [ESMO]

Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist® [Novartis]

Blocking PD1 Shows Promise in Merkel Cell Carcinoma [ESMO]

Greater Clinical Benefit Obtained in Advanced BRAFV600-mutated Melanoma with Cobimetinib/Vemurafenib Over Vemurafenib Is Consistent Across Mutation Subtypes [ESMO]

A Combination of Two Targeted Therapies Results in Melanoma Patients Living Significantly Longer: new results [ESMO]

Drug Combination Improves Progression-Free Survival in Melanoma Patients Regardless of Genetic Status, Age and Spread of Disease [ESMO]

5.6.6 ESMO - Sein

Two Large International Studies Provide Additional Prospective Data Reinforcing the Ability of Oncotype DX® to Accurately Predict Clinical Outcomes in Early-Stage Breast Cancer Patients [Genomic Health]

TAILORx trial finds 99 percent of women with low Oncotype DX® Recurrence Score® are free of breast cancer recurrence after five years of hormone therapy alone [Genomic Health]

Gene Test Helps Some Breast-Cancer Patients Skip Chemo, Study Says [Wall Street Journal]

TURANDOT: First-Line Bevacizumab Plus Capecitabine Shows Non-Inferior Overall Survival versus Bevacizumab plus Paclitaxel for Metastatic Breast Cancer [ESMO]

Hormonal Therapy Could Prevent Ovarian Failure and Preserve Fertility in Women with Breast Cancer [ESMO]

ESMO Commentary: Preliminary Results from PERUSE Study Increase Treatment Options in HER-Positive Patients with Metastatic Breast Cancer [ESMO]

5.6.7 ESMO - Immunothérapies

New Findings Show Anti-Tumor Activity of KEYTRUDA® (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma [Merck]

Novel Assay Developed to Determine PD-L2 Expression in Tumour Samples [ESMO]

ESMO Commentary: Immune therapy brings new treatment options for lower GI cancers [ESMO]

Roche says new drug shows benefits in lung, bladder cancer tests [Reuters]

5.6.8 ESMO - Côlon-rectum

Discovery of differences between tumours of younger and older colorectal cancer patients may lead to better treatments [ESMO]